This also includes an awareness of marker limitations—for instance, p63 cross-reactivity in myoepithelial tumors or CK5/6 expression in some basal-type adenocarcinomas—which underscores the need for multi-marker strategies and internal controls [30,66,67,82]. The gene discussed is KRT5; the disease is adenocarcinoma.